{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:16:03Z","timestamp":1791483363178,"version":"4.3.4"},"reference-count":135,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":245,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) and chronic heart failure (HF) frequently coexist and, when comorbid, are associated with poorer outcomes. These two diseases have common risk factors, such as diabetes, obesity and hypertension, and common pathophysiological connected mechanisms, including inflammation, endothelial dysfunction, neurohormonal activation and fibrosis. Early diagnosis and intervention are important to slow CKD progression and reduce HF events. Shared therapeutic targets for CKD and HF include the renin\u2013angiotensin system (RAS), sodium-glucose cotransporter 2 (SGLT2), mineralocorticoid receptor (MR) and glucagon-like peptide-1 (GLP-1) receptor. For the management of CKD, current treatment guidelines recommend the use of RAS inhibitors, SGLT2 inhibitors, the nonsteroidal MR antagonist finerenone and GLP-1 receptor agonists. Challenges in the management of patients with CKD and HF include the presence of other comorbidities, leading to polypharmacy. This review highlights gaps and opportunities for improving the management of patients with CKD and chronic HF.<\/jats:p>","DOI":"10.1002\/ehf2.15345","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:40:27Z","timestamp":1750286427000},"page":"3226-3249","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Interconnected Pathways and Emerging Therapies in Chronic Kidney Disease and Heart Failure: A Comprehensive Review"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-117X","authenticated-orcid":false,"given":"Johann","family":"Bauersachs","sequence":"first","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri Toda","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[{"name":"George Washington University , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2026021804192237500_ehf215345-bib-0001","first-page":"S1","article-title":"US Renal Data System 2023 annual data report","volume":"83","author":"United States Renal Data System","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026021804192237500_ehf215345-bib-0002","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000520909","article-title":"Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities","volume":"12","author":"Vijay","year":"2021","journal-title":"Cardiorenal Med"},{"key":"2026021804192237500_ehf215345-bib-0003","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ejhf.3112","article-title":"The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry","volume":"26","author":"Tomasoni","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0004","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/CIRCRESAHA.122.321748","article-title":"The cardio-kidney patient: epidemiology, clinical characteristics and therapy","volume":"132","author":"Schuett","year":"2023","journal-title":"Circ Res"},{"key":"2026021804192237500_ehf215345-bib-0005","volume-title":"2023 annual report","author":"U.S. Department of Health and Human Services"},{"key":"2026021804192237500_ehf215345-bib-0006","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2026021804192237500_ehf215345-bib-0007","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026021804192237500_ehf215345-bib-0008","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ahj.2023.11.008","article-title":"Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure","volume":"267","author":"Savarese","year":"2024","journal-title":"Am Heart J"},{"key":"2026021804192237500_ehf215345-bib-0009","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18.273","article-title":"Prognostic impact of chronic kidney disease in patients with heart failure","volume":"23","author":"Hakopian","year":"2019","journal-title":"Perm J"},{"key":"2026021804192237500_ehf215345-bib-0010","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/s0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"2026021804192237500_ehf215345-bib-0011","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0012","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026021804192237500_ehf215345-bib-0013","doi-asserted-by":"publisher","first-page":"c204","DOI":"10.1159\/000201568","article-title":"Focus on microalbuminuria to improve cardiac and renal protection","volume":"111","author":"de Jong","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"2026021804192237500_ehf215345-bib-0014","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.0831","article-title":"Prevalence of and factors associated with undiagnosed stage 3 chronic kidney disease in patient with a history of heart failure: a report from REVEAL-CKD","volume":"42","author":"Wittbrodt","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804192237500_ehf215345-bib-0015","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S0735-1097(22)01431-0","article-title":"Undiagnosed stage 3 chronic kidney disease in patients with a history of heart failure: a report from REVEAL-CKD","volume":"79","author":"Moriyama","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0016","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/ejhf.3210","article-title":"Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. veterans with heart failure","volume":"26","author":"Patel","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0017","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jama.2015.0602","article-title":"Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review","volume":"313","author":"Levey","year":"2015","journal-title":"JAMA"},{"key":"2026021804192237500_ehf215345-bib-0018","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0019","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure: JACC state-of-the-art review","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0020","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10157-019-01842-2","article-title":"High-normal albuminuria is strongly associated with incident chronic kidney disease in a nondiabetic population with normal range of albuminuria and normal kidney function","volume":"24","author":"Okubo","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"2026021804192237500_ehf215345-bib-0021","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/01.Cir.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0022","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/s2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021804192237500_ehf215345-bib-0023","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cardfail.2021.10.007","article-title":"Ten-year risk-prediction equations for incident heart failure hospitalizations in chronic kidney disease: findings from the chronic renal insufficiency cohort study and the multi-ethnic study of atherosclerosis","volume":"28","author":"Mehta","year":"2022","journal-title":"J Card Fail"},{"key":"2026021804192237500_ehf215345-bib-0024","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021804192237500_ehf215345-bib-0025","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"2026021804192237500_ehf215345-bib-0026","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026021804192237500_ehf215345-bib-0027","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"},{"key":"2026021804192237500_ehf215345-bib-0028","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"},{"key":"2026021804192237500_ehf215345-bib-0029","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0030","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804192237500_ehf215345-bib-0031","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure \u2013 digest version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"2026021804192237500_ehf215345-bib-0032","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jchf.2024.08.009","article-title":"Natriuretic peptides, kidney function and clinical outcomes in heart failure with preserved ejection fraction","volume":"13","author":"Neuen","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0033","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0034","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024139","article-title":"Cardiorenal nexus: a review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials","volume":"11","author":"McCullough","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026021804192237500_ehf215345-bib-0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100705","article-title":"Heart failure with preserved ejection fraction with CKD: a narrative review of a multispecialty disorder","volume":"5","author":"Patel","year":"2023","journal-title":"Kidney Med"},{"key":"2026021804192237500_ehf215345-bib-0036","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/cir.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0037","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/circulationaha.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0038","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/hypertensionaha.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"2026021804192237500_ehf215345-bib-0039","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.kisu.2021.11.001","article-title":"Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms","volume":"12","author":"Bauersachs","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026021804192237500_ehf215345-bib-0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026021804192237500_ehf215345-bib-0041","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by finerenone-translational aspects and clinical perspectives across multiple organ systems","volume":"23","author":"Kolkhof","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026021804192237500_ehf215345-bib-0042","volume-title":"Entresto\u00ae highlights of prescribing information","author":"Novartis"},{"key":"2026021804192237500_ehf215345-bib-0043","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.662544","article-title":"Systematic review and meta-analysis of renin-angiotensin-aldosterone system blocker effects on the development of cardiovascular disease in patients with chronic kidney disease","volume":"12","author":"Yanai","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026021804192237500_ehf215345-bib-0044","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11886-018-0944-4","article-title":"The sacubitril\/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in hypertension, heart failure, and beyond","volume":"20","author":"Kario","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"2026021804192237500_ehf215345-bib-0045","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"2026021804192237500_ehf215345-bib-0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2026021804192237500_ehf215345-bib-0047","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/ndt\/gfae024","article-title":"How to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonists","volume":"39","author":"Rothberg","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804192237500_ehf215345-bib-0048","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MNH.0000000000000894","article-title":"Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease","volume":"32","author":"Alicic","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026021804192237500_ehf215345-bib-0049","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2026021804192237500_ehf215345-bib-0050","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804192237500_ehf215345-bib-0051","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026021804192237500_ehf215345-bib-0052","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026021804192237500_ehf215345-bib-0053","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100187","article-title":"The evolution of \u201cpillars of therapy\u201d to reduce heart failure risk and slow diabetic kidney disease progression","volume":"19","author":"Blazek","year":"2022","journal-title":"Am Heart J Plus"},{"key":"2026021804192237500_ehf215345-bib-0055","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/ndt\/gfac331","article-title":"The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes","volume":"38","author":"Agarwal","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804192237500_ehf215345-bib-0056","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0057","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/circulationaha.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0058","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0427","article-title":"Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review","volume":"7","author":"Colombijn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026021804192237500_ehf215345-bib-0059","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","article-title":"The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease","volume":"70","author":"Charytan","year":"2006","journal-title":"Kidney Int"},{"key":"2026021804192237500_ehf215345-bib-0060","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0061","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/circulationaha.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0062","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial","volume":"233","author":"Sarraju","year":"2021","journal-title":"Am Heart J"},{"key":"2026021804192237500_ehf215345-bib-0063","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0064","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0065","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0066","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized cinical trial","volume":"9","author":"Mc Causland","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0067","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0068","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/circulationaha.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0069","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"2026021804192237500_ehf215345-bib-0070","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0071","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0072","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0073","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2026021804192237500_ehf215345-bib-0074","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0075","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0076","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0077","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0078","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026021804192237500_ehf215345-bib-0079","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/circulationaha.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0080","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"2026021804192237500_ehf215345-bib-0081","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0082","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0083","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0084","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0085","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ejhf.2450","article-title":"Effects of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF","volume":"24","author":"Peikert","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021804192237500_ehf215345-bib-0086","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0087","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0088","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"2026021804192237500_ehf215345-bib-0089","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0090","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0091","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0092","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0093","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart hailure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0094","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"2026021804192237500_ehf215345-bib-0095","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0096","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0097","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804192237500_ehf215345-bib-0098","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0099","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0101","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0102","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/s0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2026021804192237500_ehf215345-bib-0103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804192237500_ehf215345-bib-0104","volume-title":"Carospir (spironolactone) oral suspension US PI","author":"U.S. Food and Drug Administration"},{"key":"2026021804192237500_ehf215345-bib-0105","volume-title":"INSPRA (eplerenone) tablets for oral use US PI","author":"U.S. Food and Drug Administration"},{"key":"2026021804192237500_ehf215345-bib-0106","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"2026021804192237500_ehf215345-bib-0107","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.amjcard.2012.05.049","article-title":"Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone","volume":"110","author":"Kampourides","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0108","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (randomized aldactone evaluation study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0109","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/circulationaha.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0110","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","article-title":"Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial","volume":"8","author":"Tofte","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021804192237500_ehf215345-bib-0111","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ajh\/hpac124","article-title":"The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature","volume":"36","author":"Georgianos","year":"2022","journal-title":"Am J Hypertens"},{"key":"2026021804192237500_ehf215345-bib-0112","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2026021804192237500_ehf215345-bib-0113","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026021804192237500_ehf215345-bib-0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026021804192237500_ehf215345-bib-0115","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804192237500_ehf215345-bib-0116","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026021804192237500_ehf215345-bib-0117","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.jacc.2024.03.426","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function","volume":"83","author":"Matsumoto","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0118","volume-title":"A study to determine the efficacy and safety of finerenone on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF)","author":"ClinicalTrials.gov"},{"key":"2026021804192237500_ehf215345-bib-0119","volume-title":"A study to determine the efficacy and safety of finerenone and SGLT2i in combination in hospitalized patients with heart failure (CONFIRMATION-HF) (CONFIRMATION)","author":"ClinicalTrials.gov"},{"key":"2026021804192237500_ehf215345-bib-0120","volume-title":"A study to evaluate finerenone on clinical efficacy and safety in patients with heart failure who are intolerant or not eligible for treatment with steroidal mineralocorticoid receptor antagonists (FINALITY-HF)","author":"ClinicalTrials.gov"},{"key":"2026021804192237500_ehf215345-bib-0121","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"2026021804192237500_ehf215345-bib-0122","doi-asserted-by":"publisher","first-page":"2","DOI":"10.14740\/cr1434","article-title":"Assessment of volume status in hospitalized patients with chronic heart failure","volume":"14","author":"Raco","year":"2023","journal-title":"Cardiol Res"},{"key":"2026021804192237500_ehf215345-bib-0123","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13101501","article-title":"Personalized medicine in kidney disease","volume":"13","author":"Gembillo","year":"2023","journal-title":"J Pers Med"},{"key":"2026021804192237500_ehf215345-bib-0124","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10741-023-10346-x","article-title":"Assessment and management of heart failure in patients with chronic kidney disease","volume":"29","author":"Guaricci","year":"2024","journal-title":"Heart Fail Rev"},{"key":"2026021804192237500_ehf215345-bib-0125","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10741-024-10415-9","article-title":"Management of patients with heart failure and chronic kidney disease","volume":"29","author":"Wu","year":"2024","journal-title":"Heart Fail Rev"},{"key":"2026021804192237500_ehf215345-bib-0126","doi-asserted-by":"publisher","first-page":"144","DOI":"10.31083\/j.rcm2504144","article-title":"An updated review of the management of chronic heart failure in patients with chronic kidney disease","volume":"25","author":"Tumelty","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"2026021804192237500_ehf215345-bib-0127","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.jacc.2024.05.081","article-title":"Implantable cardioverter defibrillator and resynchronization therapy in patients with overt chronic kidney disease: JACC state-of-the-art review","volume":"84","author":"Varga","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021804192237500_ehf215345-bib-0128","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.120.15205","article-title":"Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure","volume":"76","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"2026021804192237500_ehf215345-bib-0129","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bjae.2022.02.003","article-title":"Diuretics and the kidney","volume":"22","author":"Bell","year":"2022","journal-title":"BJA Educ"},{"key":"2026021804192237500_ehf215345-bib-0130","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/ndt\/gfab026","article-title":"Personalizing heart failure management in chronic kidney disease patients","volume":"37","author":"Banerjee","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804192237500_ehf215345-bib-0131","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100739","article-title":"Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years","volume":"32","author":"Lawson","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026021804192237500_ehf215345-bib-0132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2024.101345","article-title":"Underuse of heart failure medications and poor long-term prognosis in chronic heart failure patients with polypharmacy - a report from the CHART-2 study","volume":"50","author":"Fujihashi","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026021804192237500_ehf215345-bib-0133","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006540","article-title":"Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease","volume":"6","author":"Cooper","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026021804192237500_ehf215345-bib-0134","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/circulationaha.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"2026021804192237500_ehf215345-bib-0135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"2025","author":"Agarwal","journal-title":"N Engl J Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/5\/3226\/66969601\/eschf_12_5_3226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/5\/3226\/66969601\/eschf_12_5_3226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:19:30Z","timestamp":1771406370000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/5\/3226\/8488236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":135,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15345","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"2025-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}